Skip to main content

Table 4 Prediction of population coverage

From: Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii

 

Class I

Population/Area

Coverage a

Average hit b

PC90 c

Australia

28.90%

1.30

0.14

Europe

41.46%

0.98

0.17

North Africa

27.32%

0.45

0.14

North America

11.29%

0.24

0.11

North-East Asia

18.86%

0.74

0.12

Oceania

34.09%

1.69

0.15

Other

22.13%

0.59

0.13

South America

0.42%

0.00

0.10

South-East Asia

37.73%

1.84

0.16

South-West Asia

34.29%

1.09

0.15

Sub-Saharan Africa

13.14%

0.23

0.12

Average (Standard deviation)

24.51% (12.06%)

0.83 (0.58)

0.14 (0.02)

  1. a projected population coverage for SAG1224-232 (KSFKDILPK); GRA6164-172 (AMLTAFFLR);GRA7134-142 (RSFKDLLKK); SAG2C13-21 (STFWPCLLR); SPA250-258(SSAYVFSVK); SPA89-98 (AVVSLLRLLK).
  2. b average number of epitope hits/HLA combinations recognized by the population
  3. c minimum number of epitope hits/HLA combinations recognized by 90% of the population.
  4. Population coverage was calculated using the analysis resource available at the IEDB http://www.iedb.org, and as described by Bui et al. 2006 [PMID 16545123]. Calculations are based on HLA genotypic frequencies obtained from the dbMHC database http://www.ncbi.nlm.nih.gov/mhc/. Population coverage reflects the fraction of individuals predicted to respond the epitope set inclusive of SAG1224-232 (KSFKDILPK), GRA6164-172 (AMLTAFFLR), GRA7134-142 (RSFKDLLKK), SAG2C13-21 (STFWPCLLR), SPA250-258 (SSAYVFSVK), and SPA89-98 (AVVSLLRLLK). The value shown corresponds to the average coverage across 11 different major geographical areas.
Back to article page

Immunome Research

ISSN: 1745-7580